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Human papillomavirus type 6 (HPV6) causes benign epithelial proliferations of the anogenital and aerodigestive tract, which
usually tend to regress spontaneously. The low incidence of HPV6 in carcinomas and the rare progression of the benign tumors
has led to the classification of HPV6 as ‘‘low-risk’’ virus. A series of reports, however, described the isolation of HPV6 variants
from malignant tumors characterized by sequence rearrangements in the noncoding regulatory region (NCR). It was speculated
that these sequence alterations play a role in tumor progression by enhancing the promoter activity and thereby increasing the
expression of the viral oncogenes E6 and E7. To elucidate if HPV6 isolates from malignancies do regularly exhibit sequence
alterations in the regulatory region we first determined and compiled the sequences of the NCRs of a number of isolates from
benign and malignant lesions. This analysis revealed in general a high degree of sequence conservation between the individual
isolates. Most of the isolates, however, differed, independently of origin, by a major and one or two minor insertions from the
prototype HPV6b sequence. When tested in a functional assay these altered NCR sequences did not result in significantly
different activities of the promoters responsible for the expression of the E6 and E7 genes. Further analysis of the E6 and E7
coding region revealed a surprisingly high sequence variability within the E6 ORF and allowed the detection of amino acid
exchanges unique for isolates from carcinomas. q 1996 Academic Press, Inc.
INTRODUCTION the E6 and E7 proteins to the tumor suppressor proteins
p53 and p105-RB, respectively (Dyson et al., 1989; Heck
Human papillomaviruses (HPV) are small DNA viruses et al., 1992). Mutational analyses revealed that the
which are associated with epithelial tumors of the skin weaker binding affinity of the low-risk HPV6 E7 protein
or the mucosa. An etiological role of HPVs in the develop- to pRB is caused by a single amino acid exchange at
ment of anogenital cancer has been well established and position 22 in comparison to HPV16 E7 (Sang and Bar-
is most clearly demonstrated for cervical cancer which is bosa, 1992; Heck et al., 1992). Both p53 and pRB are
positive for HPV DNA in over 90% of the cases (zur Hau- important regulator proteins of cell cycle progression and
sen, 1991). Certain papillomaviruses, like HPV16 and 18, their functions are severely impaired by complex forma-
are highly prevalent in anogenital carcinomas and are tion with the E6 and E7 oncoproteins of high-risk viruses
therefore considered to have a high carcinogenic poten- (Huibregtse and Scheffner, 1994; Vousden, 1995).
tial, whereas the ‘‘low-risk’’ genital types HPV6 and 11 High- and low-risk genital HPVs, however, do not differ
are mainly associated with benign epithelial prolifera-
only in the properties of their E6 and E7 proteins but also
tions, like laryngeal papillomas and venereal warts (Lor-
in the transcriptional regulation of their oncogenes. The
incz et al., 1992; Kadish et al., 1992; Steinberg, 1987).
E6 and E7 genes of HPV16 and HPV18 are transcribed
Experimental data suggest that the carcinogenic poten-
from the same promoter located upstream of the E6 ORF.
tial of high-risk and low-risk genital types corresponds
Transcripts generated by splicing out one of two in-mainly with the biological and biochemical properties of
trons in the E6 ORF facilitate translation of E7, whiletheir E6 and E7 oncoproteins. A large number of studies
transcripts not spliced in the E6/E7 region serve asrevealed higher immortalizing and transforming activities
mRNA for the E6 protein. In contrast to this, a secondof the oncoproteins of HPV16 and 18 in comparison to
promoter for the generation of E7-specific transcriptsthe respective proteins of HPV6 and 11 (zur Hausen,
with major start sites around position 270 has been de-1994; Vousden, 1995). These different activities were
scribed for the low-risk types HPV6 and HPV11 (Smotkinfound to be mainly due to the higher binding affinity of
et al., 1989). The activities of these early promoters are
controlled by regulatory cis-elements residing in the non-
coding region (NCR; Turek, 1994), a genomic fragment1 To whom correspondence and reprint requests should be ad-
dressed. Fax: 09131 852101; E-mail: tsiftner@viro.med.uni-erlangen.de. of about 1 kb located between the L1 and the E6 ORF.
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Although HPV6 is generally regarded as a low-risk a higher carcinogenic potential to the respective HPV6
subtype by enhancing the activity of the early promoterstype, a number of reports describe its identification in
malignancies, including carcinomas of the vagina (Oka- and thereby increasing the expression of the E6 and E7
oncogenes (Rando et al., 1986b; Boshart and zur Hausen,gaki et al., 1984), the vulva (Rando et al., 1986a; Kasher
and Roman, 1988), the tongue (Kitasato et al., 1994), the 1986; Kasher and Roman, 1988). Functional studies at-
tempting to elucidate the influence of these sequenceurethra (Mevorach et al., 1990), the bladder, and the cer-
vix (Wilcynski et al., 1993; Oft et al., 1993) and in a tonsillar rearrangements on the promoter strength were per-
formed in the context with a heterologous promoter orcarcinoma (Bercovich et al., 1991). In a recent study
where we investigated 318 invasive carcinomas of the in one case with the HPV6 E6 promoter (Rando et al.,
1986b; Wu and Mounts, 1988; Kulke et al., 1989; Farr etlower genitourinary tract, we found three tumors to be
exclusively positive for HPV6 by Southern blot, PCR, and al., 1991). The E7 promoter, however, was never included
in any of the former studies, although E7 is the majorin situ hybridization, representing approximately 1% of all
investigated cases (Wilczynski et al., 1993). In addition, transforming protein of the genital HPV types (Huibregtse
and Scheffner, 1994; Vousden, 1995). Furthermore, in situBuschke–Lo¨wenstein tumors, which are invasively grow-
ing verrucous genital tumors, are clinically regarded as hybridization studies have shown a specific upregulation
of the E7 but not of the E6 transcription along with tumormalignant and are most often associated with HPV6
(Boshart and zur Hausen, 1986; Ru¨bben et al., 1992). progression (Oft et al., 1993; Iftner et al., 1992). Above
that, the coding region encompassing the oncogenes E6Malignant progression associated with papillomavi-
ruses is often accompanied by alterations in the viral and E7 has not been investigated so far for nucleotide
sequence exchanges which could give rise to the expres-DNA. In cervical carcinomas containing high-risk HPVs
the viral DNA was frequently found integrated into the sion of altered oncogene products. This prompted us to
investigate if distinct alterations in the genomic regionhost genome (Boshart et al., 1984; Schwarz et al., 1985;
Yee et al., 1985). In most cases the integration event encoding E6 and E7 correlate with the occurrence of
HPV6 in malignant lesions and if sequence rearrange-leads to the removal of an RNA instability element and
to the interruption of the ORF E2 which encodes a tran- ments in the noncoding regulatory region indeed contrib-
ute to an increased expression of the viral oncogenes.scriptional repressor of the early promoter. As a conse-
quence expression of the viral oncogenes E6 and E7 is Our results do not support the existence of distinct HPV6
subtypes with a high carcinogenic potential as has beenupregulated (Thierry and Yaniv, 1987; Bernard et al., 1989;
Romanczuk et al., 1990; Jeon and Lambert, 1995). In con- suggested in earlier reports (Rando et al., 1986b; Boshart
and zur Hausen, 1986; Kasher and Roman, 1988; Kulketrast to the high-risk genital HPVs, integration of the viral
genome has not been detected in HPV6-positive carcino- et al., 1989). However, we found a certain degree of vari-
ability especially in the coding sequences for the E6mas (Oft et al., 1993) with the exception of a single case
reported by Bercovich et al. (1991). Detailed analyses of proteins among all isolates investigated and we ob-
served few specific amino acid exchanges in the E6 andthe viral DNA, however, frequently detected sequence
rearrangements within the regulatory noncoding region E7 proteins unique for HPV6 isolates from carcinomas.
in comparison to the prototype HPV6b DNA, and these
isolates were designated HPV6 subtypes (de Villiers et MATERIALS AND METHODS
al., 1981; Schwarz et al., 1983; Rando et al., 1986a; Bosh-
Patients and specimensart and zur Hausen, 1986; Kasher and Roman, 1988;
Kulke et al., 1989; Farr et al., 1991). Meanwhile a series All 16 specimens analyzed in this study were shown
of such HPV6 subtypes has been isolated from malignant by PCR to contain exclusively DNA of HPV6. The isolation
lesions, like 6d (Boshart and zur Hausen, 1986), HPV6vc and initial characterization of HPV6 variants from the
(Rando et al., 1986a), and 6-T70 (Kasher and Roman, bladder and the cervical carcinoma were previously de-
1988), as well as from benign tumors, like 6a (Gissmann scribed (Wilczynski et al., 1993). Further, we analyzed an
et al., 1982; Gissman and zur Hausen, 1980; Boshart and HPV6 isolate from a verrucous carcinoma of the vulva
zur Hausen, 1986), 6e (Mounts et al., 1982), 6g (Wu and and from 13 condylomata from the following sites: vulva
Mounts, 1988), 6ma (Kulke et al., 1989), and 6-W50 (Farr (6), urethra (2), larynx (2), and 1 each from the vagina,
et al., 1991). Sequence alterations have been described penis, and perianal region.
either in the L1 proximal part of the NCR, where various
insertions have been reported (Rando et al., 1986a; Isolation of cellular DNA from tumor material
Kasher and Roman, 1988; Farr et al., 1991; Boshart and
zur Hausen, 1986), or in the 3*-end of the NCR, where a Biopsy material was lysed in 50 mM Tris, pH 7.5, 10
mM EDTA, 2% sodium lauroyl sarcosinate for 30 min atspecific group of subtypes, like 6d, 6ma, and 6g, carry
large duplications (Boshart and zur Hausen, 1986; Kulke 567. RNA and proteins were digested with 250 ng/ml
RNase A (Boehringer Mannheim, Mannheim, Germany)et al., 1989; Wu and Mounts, 1988). It was speculated
that these sequence alterations in the NCR might confer and 500 ng/ml protease K (Boeringer Mannheim). Each
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step was performed at 377 for 1 hr. The lysate was ex- struction of the b-galactosidase expression vector CMV-
bGal, the b-galactosidase gene was isolated from thetracted twice with phenol:chloroform (1:1) and once with
chloroform, and subsequently ethanol precipitated (Wilc- pCH110 plasmid (Pharmacia, Uppsala, Sweden) by Hin-
dIII– BamHI digestion, purified by gel electrophoresis,zynski et al., 1993; Oft et al., 1993).
and cloned downstream of the CMV early promoter into
Polymerase chain reaction the HindIII– BamHI sites of the pCB6 eukaryotic expres-
sion vector (a gift kindly provided by M. Stinski). The
For cloning of the luciferase constructs a genomic re-
amplification products derived from the E6 and E7 region
gion encompassing the NCR and the early promoters
were cloned into pBluescript II (KS//0) (Stratagene, La
was amplified by PCR from different HPV6 subtypes with
Jolla, CA). Before ligation the vector was cleaved by
the help of the primer pair 6-1 and 6-2. Primer 6-1 hybrid-
EcoRV, and a dideoxy(T) overhang was generated with
izes to sequences at positions 7138–7159 of the HPV6b
T7 DNA polymerase. Plasmid DNA for sequencing and
genome (Schwarz et al., 1983) and contains an additional
transfection analyses was prepared with the Qiagen
SalI restriction site and primer 6-2 binds to sequences
plasmid preparation kit (Diagen, Du¨sseldorf, Germany).
at positions 445–425 and contains an additional BglII
restriction site. Five nanograms of cloned plasmid DNA Sequence analyses
of HPV6b (de Villiers et al., 1981), 6a (Gissmann et al.,
1983), 6d (Boshart and zur Hausen, 1986), 6ma (Kulke et Sequence analysis of the NCRs was performed with
the Pharmacia kit (Pharmacia) following the manufactur-al., 1989), and 6vc (Rando et al., 1986a) or 1 mg of total
DNA from the bladder carcinoma was used as template er’s instructions. Oligonucleotides with the following nu-
cleotide positions of the HPV6b genome (Schwarz et al.,for PCR amplification. The PCR reactions were performed
in a 50-ml volume containing 50 mM KCl, 10 mM Tris, pH 1983) were used as primers: pr. 6-1 and 6-2 (see above),
pr. 6-3 (nt 51–79), pr. 6-4 (nt 79–51), pr. 6-5 (nt 157–136),8.3, 1.5 mM MgCl2 , 0.01% gelatin, 200 mM dNTP mix, 0.4
mM each primer, and 2.5 U Taq polymerase (Perkin – pr. 6-6 (nt 7424–7447), pr. 6-7 (nt 7447–7424), pr. 6-8
(nt 7746–7764), pr. 6-9 (nt 7489–7471); primer pA-lucElmer) with 30 cycles of denaturation (947, 45 sec), an-
nealing (507, 60 sec), and extension (727, 80 sec). Each hybridizes to the N-terminal part of the luciferase gene
(nt 110–92 in pA-luc). The sequence reactions were sep-sample was overlaid with mineral oil to prevent evapora-
tion. Before amplification the DNA was denatured at 947 arated on a 6% urea polyacrylamide gel, dried, and sub-
sequently autoradiographed for 2 days. The sequencefor 2 min and an additional extension step of 727 for 5
min was included at the end of the reaction. For PCR comparison was done with the help of the Pileup pro-
gram from GCG Wisconsin Package (Madison, WI). Theamplification of the E6 and E7 region of different HPV6
subtypes from biopsy material or plasmid DNA, the prim- analysis of the E6 and E7 region was performed by se-
quencing at least two clones derived from independenters 6-E6-035 (positions 35–66) and 6-E7-824 (positions
824–794) were used. The PCR conditions used were PCR reactions with the help of an automatic sequencer
and the Prism Ready Reaction dyedideoxy terminator cy-slightly different. The reactions were performed with 0.5
mg biopsy DNA or 1 pg prototype HPV6b plasmid DNA cle sequencing kit (Applied Biosystems, Inc., Foster City,
CA). In cases where we detected unique amino acid(de Villiers et al., 1981) in 200 nM each dNTP, 50 mM
KCl, 10 mM Tris, pH 8.3, 6 mM MgCl2 , 0.4 mM each exchanges we directly sequenced uncloned amplifica-
tion products obtained from biopsy DNA to exclude clon-primer, and 2.5 U Taq polymerase with 40 cycles of dena-
turation (957, 30 sec), annealing (557, 30 sec), and exten- ing artifacts. The T3, T7, SK, and KS oligonucleotides
(Stratagene) and the oligonucleotides 6bE6-1A and 6-E6-sion (727, 60 sec).
411 hybridizing to nt 114–143 and nt 411–440 of the
Plasmid constructions HPV6b genome, respectively, were all used as primers.
All sequences were determined from overlapping
PCR fragments obtained after amplification with the
stretches from both strands of the DNA.
primers 6-1 and 6-2 were phenol extracted, ethanol pre-
cipitated, digested with the restriction enzymes SalI and Cell culture and transfections
BglII (Gibco BRL, Eggenstein, Germany), and subse-
quently ligated with the SalI–BamHI site of the luciferase Transfection experiments were performed in the HPV-
negative cervical carcinoma cell line HT3 (ATCC HTB32),expression vector pA-luc (Dong et al., 1994). The clones
obtained were named 6aI-luc, 6b-luc, 6d-luc, 6ma-luc, in the skin-derived keratinocyte line RTS3b (Purdie et
al., 1993), and in HPV16 E7-immortalized human foreskinand 6vc-luc according to the HPV6 subtype from which
they were derived; the plasmid carrying the HPV6 frag- keratinocytes (HFK) (Schmitt et al., 1994). HT3 cells were
cultivated in Dulbecco’s modified Eagle’s medium (Gibcoment from the bladder carcinoma was designated 6bc-
luc. Due to restriction enzyme analyses all clones con- BRL) supplemented with 10% fetal calf serum (Gibco
BRL), 2.5 mg/ml amphotericin B (Fungizone; Gibco BRL),tained the HPV6 genomic fragment in sense orientation
which was further verified by sequencing. For the con- and 50 mg/ml gentamycin (Gibco BRL). RTS3b and HFK
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cells were cultivated in E-medium as described pre- C18 columns (Waters; Millipore, Bedford, MA). Fifty nano-
grams of the oligonucleotide was labeled with [g-32P]ATPviously (Grassmann et al., 1996). Five micrograms of the
luciferase construct DNA and 1.0 mg of CMV-bGal DNA using T4 polynucleotide kinase (Gibco BRL). Nonincorpo-
rated nucleotides were separated from the labeledwere transfected in subconfluent (60%) cells on 60-mm
plates using a modified calcium phosphate coprecipita- primer by Sephadex G50 columns. Twenty micrograms
of biopsy RNA or 50 mg of RNA extracted from 6aI-luc-tion method (Graham and van der Eb, 1973) which was
described before (Iftner et al., 1988). Forty-eight hours transfected cells was annealed to 100,000 cpm of the
labeled primer in 100 mM NaCl, 20 mM Tris–HCl, pHposttransfection the cells were scraped off the plates,
pelleted by centrifugation, and dissolved in 100 ml of 8.3, 0.1 mM EDTA by heating the samples (907 for 3 min,
557 for 10 min) and slowly cooling them down to 427. Theextraction buffer consisting of 100 mM potassium phos-
phate, pH 7.8, and 1 mM DTT. Subsequently, the cells reverse transcription reaction was carried out at 427 for 1
hr with 200 U M-MLV reverse transcriptase (Superscript;were lysed by repeated cycles of shock freezing in liquid
nitrogen and thawing, and the suspension was centrifu- Gibco BRL) in the buffer supplied by the manufacturer
(Gibco BRL) supplemented with 1 mM dNTPs, 20 mg/mlgated at 47 to separate the cell debris from the superna-
tant cell protein extract. The protein concentration was actinomycin D, 4 mM DTT, 100 mg/ml BSA. The extension
products were extracted once with phenol:chloroformdetermined with the help of the BCA protein assay kit
(Pierce, Rockford, IL) following the manufacturer’s in- (1:1), precipitated, and separated on a 6% denaturing
acrylamide gel.structions.
Luciferase and b-galactosidase assays RESULTS
The luciferase activity was measured according to de NCR sequence comparison between HPV6 subtypes
Wet et al. (1987). Briefly, 40 ml of the protein extract was isolated from malignant and benign tumors
added to 100 ml assay buffer containing 100 mM potas-
To investigate if HPV6 isolates from malignant tumors
sium phosphate, pH 7.8, 15 mM MgSO4 , 5 mM rATP. The harbor distinct sequence rearrangements in the NCR we
luciferase activity was measured in relative light units
performed a comprehensive comparison of the NCR se-
(RLU) after injection of the 1 mM D-luciferin solution (Boe-
quences of seven HPV6 isolates. Since HPV6a has been
hringer Mannheim) dissolved in assay buffer, with the
shown to be a very common subtype in condylomata (Giss-
help of a luminometer (Berthold LB9051). The values de-
mann et al., 1983; Roman and Brown, 1995) we sequenced
termined were subsequently standardized to the amount
the complete NCR and early promoter region of the origi-
of input protein and are indicated as RLU/mg protein.
nally described HPV6a clone (HPV6aI; Gissmann and zur
To normalize the transfection efficiency, 1.0 mg of a b-
Hausen, 1980; Gissman et al., 1982; Boshart and zur Hau-
galactosidase expression vector (CMV-bGal) was co-
sen, 1986). In addition, the corresponding genomic region
transfected in all plates. Observed differences in trans-
from an HPV6-positive bladder carcinoma was cloned and
fection efficiencies between plates of one experiment
subsequently sequenced. Although we noted in a previous
were then equalized according to the b-galactosidase
study that the restriction enzyme cleavage pattern of the
assay determined from 10 ml of cell extract with the help
NCR of this isolate resembled that of HPV6a (Oft et al.,
of the ONPG (O-nitrophenyl-b-D-galactose pyranoside)
1993) we designated this variant HPV 6bc (for bladder carci-
assay described in Sambrook et al. (1989). To normalize
noma) for better discrimination from benign subtypes. Very
the results from the luciferase assays the RLU/mg values
recently the complete sequence of another HPV6a isolate
were divided by the relative b-galactosidase activity
from a vulvar condyloma was described (Hofmann et al.,
which was determined by the formula: OD420nm 1 1000/ 1995) and we included this sequence as HPV6aII in our
mg protein.
analysis. Figure 1 shows the comparison of the NCR se-
quences of the prototype HPV6b (Schwarz et al., 1983),RNA extraction and primer extension analyses
HPV6aI, 6aII, and 6-W50 (Farr et al., 1991), all originating
from condylomata, with the NCR sequences of isolatesTwenty micrograms of 6aI-luc DNA was transfected
into HT3 and RTS3b cells cultivated in 100-mm plates in from a bladder carcinoma (6bc) and two vulvar carcinomas
(6vc, Rando et al., 1986a; and 6-T70, Kasher and Roman,two independent experiments. Forty-eight hours post-
transfection the cells were harvested, and total cell RNA 1988). Interestingly, all sequences showed a remarkably
high degree of homology except for one major and twowas extracted according to Chomczynski and Sacchi
(1987). RNA from the bladder carcinoma and a condy- minor insertions in comparison to the prototype HPV6b
sequence. 6aI, 6aII, 6-W50, and 6bc contained an almostloma was isolated by the guanidium hydrochloride
method (Chirgwin et al., 1979). The primer extension identical 94-bp insertion at position 7347 of the HPV6b
sequence which is highly homologous to the 74- and 66-analyses were performed with the help of the oligonucle-
otide E6-366 (nt 366–348) which was purified by re- bp insertions at the same position in 6vc and 6-T70, respec-
tively (Fig. 1). The large insertion is located in the 3*-untrans-versed-phase chromatography with the help of Sep-Pak
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FIG. 1. Comparison of the NCR sequences of different HPV6 subtypes. The NCR sequences of the original HPV6a clone named HPV6aI (Gissmann
et al., 1982; Boshart and zur Hausen, 1986) and from an HPV6 isolate from a bladder carcinoma (6bc) were determined and compared with the
described NCR sequences of HPV6a cloned from a vulvar condyloma designated 6aII (Hofmann et al., 1995), HPV6-W50 (Farr et al., 1991), HPV6b
(Schwarz et al., 1983), HPV6vc (Rando et al., 1986a), and HPV6-T70 (Kasher and Roman, 1988). Stars illustrate identical nucleotides with the HPV6aI
sequence, dashes demonstrate missing nucleotides. The three insertions in comparison to the HPV6b sequence are indicated above the sequence.
The large insert at position 7347 consists of 66 bp (6-T70), 74 bp (6vc), or 94 bp (6aI, 6aII, 6bc, 6-W50); the two minor insertions at positions 7419
and 7719 comprise 13/14 bp and 19/20 bp, respectively. Further, the four binding sites for the viral transcription factor E2 (E2-BS), the late poly(A)
signal (Poly-A), and the E6 promoter at position 90 (P90-promoter) with its corresponding TATA box (TATA) are indicated above the nucleotide
sequences. Nucleotide positions are indicated according to the HPV6b sequence (Schwarz et al., 1983).
lated region of the L1 open reading frame and consists of In addition to the above-described sequence inser-
tions, a number of minor differences have been detecteda Pu-T-rich sequence. Two minor insertions have been
detected at positions 7719 and 7419 which do not occur mainly in the L1-proximal and in the middle part of the
NCR. Twenty-four point mutations, four single base pairin all subtypes. HPV6aI, 6aII, and 6bc contain a 20-bp inser-
tion at position 7719 differing only by an additional T and deletions, and two insertions of 1 or 2 bp have been
identified among all subtypes on the total length of theone A r T transversion from the 19-bp insertion in 6vc.
Another highly homologous sequence insertion of 13/14 bp NCR. Most point mutations were not randomly distributed
but were found to be common to groups of isolates.at position 7419 could be identified for the subtypes 6aI,
6bc, and 6vc, respectively. Surprisingly, it was missing in Several isolates share common sequence features so
that roughly two groups can be distinguished consistingthe recently sequenced HPV6aII NCR. Similar to 6b, the
NCRs of 6-W50 and 6-T70 contained neither the 13/14-bp of 6b, 6-T70, and 6-W50 on one hand and 6aI, 6aII, 6bc,
and 6vc on the other hand. The relationships betweennor the 19/20-bp insertions. 6-T70 was further different from
all other subtypes by a 32-bp deletion which occurred next different subtypes based on their NCR sequence homolo-
gies are graphically represented in the dendrogram into the 66-bp insertion. A small deletion of 6 bp was ob-
served in the newly cloned 6aII at position 7419 which is Fig. 2. Importantly, HPV6 variants isolated from malignant
lesions (6-T70, 6bc, 6vc) did not segregate by specific-next to the 14-bp insertion region.
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whereas HPV 6d and 6ma additionally showed large du-
plications of 459 bp from positions 7528–7987 and of
236 bp from positions 7681–7896, respectively. From all
these subtypes we cloned a fragment containing the
complete NCR and the two HPV6 early promoters in
sense orientation upstream of the luciferase gene of the
promoterless luciferase expression vector pA-luc (Dong
et al., 1994). The luciferase constructs were designated
6aI-luc to 6vc-luc according to the subtype from which
the NCR sequence was derived. First it was necessary
to show that both the E6 and the E7 promoter are active
in these luciferase constructs. For this, 6aI-luc was trans-
fected into the HPV-negative cervical carcinoma cell line
HT3 (ATCC HTB32) and into the HPV-negative skin-de-
rived cell line RTS3b (Purdie et al., 1993), and total RNA
was extracted. Primer extension analyses were per-
formed with 50 mg of total RNA and an end-labeled primer
(E6-366) complementary to the HPV 6 sequence between
positions 366 and 348. In RTS3b cells the observed ex-
tension products of 96 and 276 nt corresponded to tran-
scripts initiating at the E7 promoter at position 270 or
FIG. 2. Relationships between different HPV6 subtypes. The dendro- the E6 promoter at position 90, respectively (Fig. 4A). In
gram shows the relationships between HPV6 subtypes according to
addition, we observed in RNA isolated from HT3 cells atheir NCR sequence homologies. Most related subtypes are positioned
series of specific bands of molecular weights rangingnext to one another in the diagram. Due to similarities in the NCR
sequences two groups can be defined comprising subtypes HPV6b, 6- from 62 to 195 nt pointing to more heterogeneous start
T70, and 6-W50 in group I and subtypes 6aI, 6bc, 6aII, and 6vc, in sites of transcription between positions 304 and 201
group II. around the E7 promoter as in RTS3b cells (data not
shown). To verify if the extension products detected with
RNA from 6aI-luc-transfected cells correspond to natu-sequence alterations in the NCR from variants isolated
rally occurring start sites of E6 and E7 transcripts presentfrom benign tumors (6aI, 6aII, 6b, 6-W50). Our data do
in HPV6 infected lesions, a primer extension analysisnot therefore support the existence of striking sequence
was performed with RNA from a bladder carcinoma anddifferences in the NCR between HPV6 variants isolated
a condyloma which confirmed the positions of the majorfrom benign or malignant tumors as suggested by earlier
transcript initiation sites at nt 90 and 270. Therefore thesereports.
data strongly suggest that both early promoters of HPV6
were active in our transient transfection experiments andInfluence of NCR sequence rearrangements of
contributed to the measured luciferase activity.different HPV6 subtypes on the activities of the
Subsequently, at least four independent transfectionhomologous HPV6 oncogene promoters
experiments were performed in HT3 and RTS3b cells and
in human foreskin fibroblasts immortalized by HPV16 E7Former investigations already tried to elucidate the
influence of NCR sequence rearrangements on the pro- (Schmitt et al., 1994) with each luciferase construct from
all six HPV6 subtypes. Transfections were always donemoter activity (Rando et al., 1986b; Wu and Mounts, 1988;
Farr et al., 1991, 1995). In almost all studies, however, in duplicate and three different DNA preparations were
tested. To evaluate and normalize the transfection effi-the heterologous SV40 early promoter was used to test
for enhancer activity. We were interested in investigating ciency 1.0 mg of a b-galactosidase expression vector
(CMV-bGal) was cotransfected in all plates. Since HPV6aif the activities of both authentic HPV6 promoters, which
are responsible for the transcription of the E6 and E7 is the most common subtype (Gissmann et al., 1983;
Ru¨bben et al., 1992; Kitasato et al., 1994), the luciferaseoncogenes under natural conditions, are affected by se-
quence rearrangements observed in the NCRs of differ- activities of all constructs given in Fig. 5 were referred
to 6aI-luc. Interestingly, transfection of 6b-luc, containingent HPV6 variants. For a comprehensive study we chose
a series of HPV6 subtypes isolated from benign (HPV6aI, the NCR of the prototype HPV6b, gave the lowest lucifer-
ase activity in all cell lines tested, whereas transfections6b, 6ma) and from malignant (HPV6vc, 6bc and 6d) tu-
mors. Figure 3 illustrates the differences in the NCRs of with 6aI-luc, 6vc-luc, and 6bc-luc resulted in almost equal
amounts of luciferase. In contrast, the luciferase con-these HPV6 isolates. The NCR sequences of HPV 6aI,
6vc, and 6bc differed by point mutations and the length structs of HPV6d and 6ma which carry large duplications
in the 3*-part of their NCRs showed in most cases signifi-of the large insert (Fig. 1) from the prototype HPV6b,
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FIG. 3. Luciferase constructs containing the complete NCRs and the early promoter region of different HPV6 subtypes. The top shows the HPV6
fragment amplified by PCR from a series of HPV6 subtypes and cloned in front of the luciferase gene (LUC). The PCR fragment spans positions
7138 to 445 according to the HPV6b sequence (Schwarz et al., 1983) containing the complete NCR and the early promoters (P90, P270). Constitutive
enhancer elements CEI and CEII identified for the closely related HPV11 (Chin et al., 1989) are outlined. Open reading frames for the viral proteins
L1, E6, and E7 as well as for the luciferase protein are indicated as open boxes. The bottom illustrates the differences in the NCRs of the isolates
HPV6b, 6a, 6bc, 6vc, 6d, and 6ma. Black boxes mark sequence insertions in comparison to the prototype HPV6b sequence. The 120-bp insertion
(gray box) in the HPV6d NCR has been defined only by restriction enzyme pattern analyses with the enzymes FnuDII/HinfI (Boshart and zur Hausen,
1986). The HPV6 isolates 6d and 6ma are characterized by tandem duplications (gray arrows) of 459 and 236 bp, respectively, in the 3*-part of their
NCRs. The nt positions and lengths of the insertions and duplications are indicated.
cantly elevated activities. These data clearly demonstrate and 3 HPV6-positive carcinomas of the bladder, the cer-
that no major difference exists in the activities of the vix, and the vulva as well as from the prototype HPV6b
early promoters between subtypes 6vc and 6bc isolated clone (de Villiers et al., 1981). The amplification products
from malignant lesions and HPV6 isolates 6a and 6b were cloned in pBluescript II (KS) and both strands of the
from condylomas. Duplications in the 3*-part of the NCR HPV6 insert were sequenced. As a control we included
caused enhanced promoter activity which could lead to HPV6b plasmid DNA and 2 condylomas proven to contain
an increased E6 and E7 expression. However, 6ma HPV11 DNA in our analysis and were able to confirm by
whose corresponding luciferase construct exhibited the sequence comparison the published HPV6b sequence
highest luciferase activity did originate from a benign as well as all described sequence deviations between
condyloma of the mamilla (Kulke et al., 1989). HPV6 and HPV11. In cases where we detected unique
amino acid exchanges in the coding region for E6 and
Differences in the E6 and E7 regions of HPV6 E7 in individual HPV6 isolates we directly sequenced
subtypes from benign versus malignant lesions uncloned amplification products obtained from biopsy
DNA to exclude cloning artifacts. Table 1 indicates allSo far we found no evidence for a higher carcinogenic
amino acid exchanges observed in the E6 and E7 ORFspotential of distinct HPV6 variants resulting from naturally
and Fig. 6 illustrates the positions of the mutations. Thisoccurring sequence alterations in the NCR. However, it
sequence analysis revealed a surprisingly high degreewould be also feasible that mutations within the coding
of variability within ORF E6 which was most striking forregion for E6 and E7 may alter the properties of the
isolates from the larynx and from immunosuppressedoncoproteins of the low-risk HPV6. Previous investiga-
and male patients. Thirteen different aa exchanges,tions revealed indeed that the substitution of a single
which are spread throughout the protein, have been de-amino acid at position 22 in HPV6 from glycine to aspartic
tected in the E6 ORF amplified from benign lesions. Upacid was responsible for an enhanced pRB binding affin-
to 6 aa exchanges have been found per individual isolate.ity and for an increased ability to cooperate with ras in
Some mutations were observed with a high frequencythe transformation of primary rodent cells (Heck et al.,
like the H r Q exchange at aa position 50 in 10 cases1992). These observations prompted us to compare the
and the N r T substitution at position 75 in 7 cases,sequences of the E6 and E7 region of HPV6 isolates from
suggesting that they prevail in naturally occurring HPV6malignant lesions with those from benign tumors. For a
viruses. Interestingly, in five E6 ORFs amplified from con-detailed analyses the E6 and E7 region was amplified
by PCR from 11 condylomata, 2 laryngeal papillomas, dylomata the cysteine at position 34 which is part of one
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Three E7 isolates did not differ at all from the prototype
HPV6b sequence and in most cases only one amino acid
was exchanged at position 38, 52, or 88. The N r D
substitution at position 88 was found in 56% of all cases.
Interestingly, three mutations occurred in the E7 region
of the isolate from the cervical carcinoma but these ex-
FIG. 4. Primer extension analyses with RNA from 6aI-luc-transfected
RTS3b cells and RNA from HPV6-positive tumors. The top shows the
primer extension analyses performed (A) with RNA from 6aI-luc-trans-
fected RTS3b cells and (B) with RNA from HPV6-positive tumors. (A)
Lane 1, RNA from RTS3b cells transiently transfected with 6aI-luc; lane
2, RNA from untransfected RTS3b cells (mock). A mixture of 5*-end-
labeled HaeIII-digestion fragments of the replicative form of FX174
and MspI-digestion fragments of pBR322 served as molecular weight
marker (M). (B) Lane 1, RNA from a bladder carcinoma; lane 2, RNA
from a condyloma, both infected with HPV6a. Numbers indicate the
lengths in nt of the observed extension products. At the bottom the
positions of the start sites of the E6 promoter (arrow, P90) and the E7
promoter (arrow, P270) as well as of the primer 6-366 (black box,
positions 366–348) in the HPV6 genome are outlined. Open reading
frames are shown as open boxes, the start codon of the E6 ORF as
an interrupted line. The lengths of the observed primer extension prod-
ucts are indicated below.
of the four highly conserved CXXC motifs was mutated
into a glycine. This alteration may impair the stability and
conformation of the E6 protein as well as Zn binding and
FIG. 5. Relative luciferase activities of the luciferase constructs ofoligomerization abilities (Barbosa et al., 1989; Roth et al.,
different HPV6 subtypes in three different cell lines. The luciferase
1992; Huibregtse and Scheffner, 1994). The three isolates constructs 6aI-luc, 6b-luc, 6bc-luc, 6d-luc, 6ma-luc, and 6vc-luc were
from carcinomas showed only few aa exchanges. All transfected in duplicate in at least four independent experiments (see
Materials and Methods) (A) in the HPV-negative cervical carcinoma cellcases carried the frequent exchange of a histidine by a
line HT3, (B) in human foreskin keratinocytes immortalized by HPV16 E7glutamine at position 50. In addition, one mutation at
(HFK) (Schmitt et al., 1994), and (C) in the skin-derived keratinocyteposition 90 was found to be unique for the isolate from
line RTS3b (Purdie et al., 1993). Differences in transfection efficiencies
the cervical carcinoma (Table 1, CA-2). were evaluated and equalized by b-galactosidase activity. The x-fold
In contrast to the extreme diversity in the E6 ORF, the luciferase activities were referred to 6aI-luc. Standard deviations are
given by bars.98 aa of the E7 protein seem to be more conserved.
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TABLE 1
Amino Acid Exchanges in the E6 and E7 ORFs of HPV6 Isolates from Benign and Malignant Tumors
Tumor Sex Source of HPV6 Isolatea AA changes in E6 ORFb AA changes in E7 ORFb
CA-1 M Invasive SCCA, bladder 50: H r Q 52: F r Y
CA-2 F Invasive SCCA, cervix 50: H r Q; 90: E r G 39: E r G; 60: G r E; 88: N r D
CA-3 F Verrucous carcinoma, vulva 50: H r Q 88: N r D
CO-1 F Vulva condyloma 50: H r Q; 75: N r T 38: D r G; 88: N r D
CO-2 M Urethra condyloma 19: T r S; 50: H r Q; 109: K r N 38: D r G
CO-3 M Urethra condyloma 50: H r Q; 75: N r H; 149: L r S 88: N r D
CO-4 F Vulva condyloma 33: F r L 38: D r G; 88: N r D
CO-5 F Vulva condyloma 50: H r Q 52: F r Y
CO-6 M Penile condyloma/AIDS patient 34: C r R; 50: H r Q; 75: N r T; 126: F r L
CO-7 M Anal condyloma/AIDS patient 50: H r Q; 75: N r T; 126: F r L 52: F r Y
CO-8 F Vaginal condyloma 109: K r N; 120: I r M
CO-9 F Vulva condyloma 34: C r G; 50: H r Q; 109: K r N 88: N r D
CO-10 F Vulva condyloma/pregnant woman 33: F r L; 34: C r G; 41: A r G; 50: H r Q; 88: N r D
75: N r T; 80: F r C
CO-11 F Vulva condyloma 33: F r L; 34: C r G
LA-1 F Laryngeal papilloma 33: F r L; 34: C r G; 50: H r Q; 75: N r T; 88: N r D
80: F r C
LA-2 M Laryngeal papilloma 33: F r L; 50: H r Q; 75: N r T; 80: F r C; 88: N r D
113: E r K; 122: T r P
a SCCA, squamous cell carcinoma.
b Numbers indicate the position of the exchanged amino acid in the E6 or E7 ORF; letters symbolize the amino acids according to the one-letter
code.
changes did not reside in the N-terminal conserved part population. The comparison of the E6 and E7 sequences
isolated from benign and malignant tumors revealed thatof the protein which contains the Rb binding site (Gage
et al., 1990). These data demonstrate a certain variability several amino acids are frequently exchanged, whereas
few exchanges are unique to individual HPV6 isolates.in the E6 and E7 ORFs of the naturally occurring HPV6
FIG. 6. Amino acid exchanges in the E6 and the E7 open reading frames of HPV6 isolates from benign and malignant tumors. The positions
of amino acid exchanges in the E6 and E7 ORFs (gray boxes) which have been observed in HPV6 isolates from 13 benign and 3 malignant
tumors are indicated. Numbers above the ORF give the position of aa exchanges in isolates from carcinomas, whereas numbers below
demonstrate aa mutations in isolates from benign tumors. The frequency (x/16) of a defined exchange is given in parentheses. Homologies
to the SV40 T-ag and the adenovirus 5 E1A protein (CR1, CR2), as well as to the RB binding site (RB) and the casein kinase II phosphorylation
sites (CKII) of HPV16 E7, and the highly conserved CXXC motifs are indicated (Gage et al., 1990; Huibregtse and Scheffner, 1994; Scheffner
et al., 1994; Vousden, 1995).
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DISCUSSION (Kulke et al., 1989) but missing in HPV6d (Boshart and zur
Hausen, 1986). Furthermore, partial sequence analyses
In comparison to the ‘‘prototype’’ HPV 6b sequence a revealed that only 10 of 15 HPV 6a variants from exo-
number of HPV 6 isolates show sequence rearrange- phytic condylomata contained the 13/14-bp insertion (Ro-
ments, like insertions and duplications in the NCR, which man and Brown, 1995), and NCR restriction enzyme pat-
contains important regulatory elements for the early pro- terns of 46 HPV6 isolates suggested that the 13/14-bp
moters. Since a series of these HPV6 subtypes was de- insertion was present in 35/46 cases (Ru¨bben et al.,
rived from malignant lesions it was speculated that these 1992).
sequence alterations might play a role in tumor progres- In addition to the sequence insertions we detected a
sion by enhancing the promoter activity and thus increas- series of minor mutations like single basepair deletions/
ing the expression of the E6 and E7 oncoproteins (Giss- insertions and point mutations between all HPV6 iso-
mann et al., 1983; Rando et al., 1986a; Wu and Mounts, lates. Interestingly, the variants from class I and class II
1988; Kasher and Roman, 1988; Kulke et al., 1989; Farr share more common nucleotides with one another than
et al., 1991). In order to elucidate if indeed specific se- with isolates belonging to class III and vice versa, which
quence alterations may account for a higher carcino- allows the definition of two major groups consisting of
genic potential of HPV6 variants isolated from malignan- 6b, 6-W50, and 6-T70 on one hand and 6aI, 6aII, 6bc,
cies we compared the NCRs and the E6 and E7 coding and 6vc on the other hand (Fig. 2). To avoid further confu-
regions of a considerable number of HPV6 isolates from sion on the topic of HPV6 subtypes it may help to group
benign and malignant tumors by sequence analyses and all future isolates according to this classification scheme.
functional assays. In conclusion, this study did not reveal sequence features
The main difference between the highly homologous which are unique to the HPV6 variants isolated from ma-
NCRs of 6aI, 6bc, 6aII, 6b, 6vc, 6-T70, and 6-W50 (Hof- lignant tumors like 6bc, 6vc, and 6-T70.
mann et al., 1995; Schwarz et al., 1983; Rando et al., To evaluate the effect of sequence alterations in the
1986a; Kasher and Roman, 1988; Farr et al., 1991) was NCRs of different HPV6 isolates on gene expression we
the presence or absence of three sequence insertions. performed functional luciferase assays. In contrast to for-
In comparison to the prototype HPV6b sequence mer studies our constructs contained the E6 and the
(Schwarz et al., 1983) all subtypes carried a highly homol- E7 promoters of HPV6 and primer extension analysis
ogous purine-T-rich sequence ‘‘insertion’’ at position 7347 confirmed that indeed both promoters were active in the
consisting of 94 bp in most cases (6aI, 6aII, 6bc, 6-W50). transient transfection experiments. Luciferase assays re-
A series of other studies reported an identical insertion vealed that the total promoter activity was only slightly
of 94 bp at the same position (Hrisomalos et al., 1990; affected by rearrangements in the 5*-part of the NCR,
Kitasato et al., 1994; Roman and Brown, 1995), sug- while the large duplications in the NCRs of HPV6d and
gesting that this stretch of 94 bp is consistently present 6ma resulted in significantly higher luciferase activities
in naturally occurring HPV6 viruses. This Pu-T-rich se- similar to data obtained with constructs under the control
quence represents a potential Z-DNA-forming sequence of a heterologous promoter (Rando et al., 1986b; Wu and
and is highly homologous to Alu repeats and medium Mounts, 1988; Kulke et al., 1989). All hitherto described
reiteration frequency repetitive elements, which have sequence duplications in the NCRs of HPV6 isolates lo-
been shown to be susceptible to recombination and rear- cate to the 3*-portion of the NCR, where the constitutive
rangement events (Aplan et al., 1992; Wahls and Moore, enhancer has been identified in the closely related
1990; Seite et al., 1993; Jurka et al., 1993). Therefore HPV11 and other genital papillomaviruses (Cripe et al.,
we suppose that rearrangements due to such sequence 1987; Gloss et al., 1987; Swift et al., 1987; Hirochika et
properties were the reason for the loss or shortening al., 1988; Chin et al., 1989; Chong et al., 1990). Thus the
of the 94-bp insertion and an additional deletion event duplication of enhancer elements is probably the reason
observed in the subtypes 6b, 6vc, and 6-T70, respectively. for the increased promoter activities of HPV6d and 6ma
These observations suggest that HPV6b should no and an increased oncogenic potential of these HPV6
longer be regarded as the prototype HPV6 virus. In con- variants due to E6/E7 overexpression is conceivable.
trast to this, we detected a real sequence polymorphism However, duplications in the NCR were not only found
for two smaller insertions of 13/14 bp at position 7419 in HPV6 isolates from malignancies but also from benign
and 19/20 bp at position 7719. According to the presence tumors (Boshart and zur Hausen, 1986; Wu and Mounts,
of these insertions three classes of variants can be dis- 1988; Kulke et al., 1989; Ru¨bben et al., 1992) and they
criminated: class I variants, including 6aI, 6bc, and 6vc, all differed in position and size. This unique character
contain both insertions; class II isolates, with 6aII as the strongly suggests that these rearrangements are not part
only member, harbor only the 20-bp insertion; whereas of distinct, efficiently propagating HPV6 variants but
the class III variants 6b, 6W-50, and 6-T70 lack both rather are secondary events which may happen during
insertions. This classification is supported by previous long-term viral persistence in infected lesions (Ru¨bben
et al., 1992). In conclusion, we observed no increasedreports, e.g., the 20-bp insertion is present in HPV6ma
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promoter activity in HPV6 variants isolated from carcino- Crawford, 1995). Mutant forms of p53 cannot substitute
for E6 in the transformation of NIH 3T3 cells (Sedman etmas. Thus the existence of more ‘‘aggressive’’ HPV6 vari-
ants characterized by an enhanced E6/E7 expression al., 1992) and transactivation of the adenovirus E2 pro-
moter by E6 is not mediated by p53 interaction (Schmittdue to sequence rearrangements in the NCR seems un-
likely. The upregulation of the E7 transcription which has et al., 1994; Tommassino and Crawford, 1995). Therefore
altered properties of the E6/E7 proteins of the differentbeen observed in HPV6-positive carcinomas (Oft et al.,
1993) is therefore not due to rearrangements in the viral HPV6 isolates cannot be excluded and further investiga-
tions would be necessary to study the transforming andgenome but rather may be caused by alterations of cellu-
lar conditions. This suggests that changes in the host immortalizing potential of these variant proteins.
are responsible for tumor progression and malignant
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